C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles (Q30899864)

27 June 2017

C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles (English)

1 reference

27 June 2017

Furlong ST

1

1 reference

27 June 2017

Dutta AS

2

1 reference

27 June 2017

Coath MM

3

1 reference

27 June 2017

Gormley JJ

4

1 reference

27 June 2017

Hubbs SJ

5

1 reference

27 June 2017

Lloyd D

6

1 reference

27 June 2017

Mauger RC

7

1 reference

27 June 2017

Strimpler AM

8

1 reference

27 June 2017

Sylvester MA

9

1 reference

27 June 2017

Scott CW

10

1 reference

27 June 2017

Edwards PD

11

1 reference

27 June 2017

1 July 2000

1 reference

27 June 2017

1 reference

27 June 2017

48

1 reference

27 June 2017

2

1 reference

27 June 2017

199-212

1 reference

Pharmacological manipulation of the complement system in human diseases

27 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Mapping the active site of papain with the aid of peptide substrates and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Structure of 3,4-dichloroisocoumarin-inhibited factor D

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Human complement component C3: cDNA coding sequence and derived primary structure

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Small-scale preparation of complement components C3 and C4

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Conformationally restrained cyclic peptides as antagonists of luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Novel inhibitors of human renin. Cyclic peptides based on the tetrapeptide sequence Glu-D-Phe-Lys-D-Trp

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Synthetic inhibitors of elastase

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 2. Effect of varying the heterocyclic ring on in vitro potency

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 3. In vitro and in vivo potency of a series of peptidyl alpha-ketobenzoxazoles

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Complement factors and their receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Prolongation of ex vivo–perfused pig xenograft survival by the complement inhibitor compstatin

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

An improved fluorogenic substrate for the alternative complement pathway C3/5 converting enzyme CVFBb

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Biologically active analogs of thymopentin with enhanced enzymatic stability

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Quenched BODIPY dye-labeled casein substrates for the assay of protease activity by direct fluorescence measurement

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Controlling the complement system in inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Control of the complement system.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Solution structure of Compstatin, a potent complement inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

A fluorimetric assay for native C3. The hemolytically active form of the third component of human complement

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

A reexamination of the role of magnesium in the human alternative pathway of complement

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Effects of D-amino acid substitution on antagonist activities of angiotensin II analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Proteolytic activity of the different fragments of factor B on the third component of complement (C3). Involvement of the N-terminal domain of Bb in magnesium binding

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

Interactions between human complement components factor H, factor I and C3b

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

EVALUATION OF THE TRYPAN BLUE TECHNIQUE FOR DETERMINATION OF CELL VIABILITY

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

A new microcellular cytotoxicity test based on calcein AM release

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900205-8

7 January 2021

10.1016/S0162-3109(00)00205-8

Identifiers

DOI

1 reference

27 June 2017

1 reference